Quemliclustat + Etrumadenant + Zimberelimab
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Oligometastatic Prostate Cancer
Conditions
Oligometastatic Prostate Cancer
Trial Timeline
Jul 1, 2023 → Dec 1, 2028
NCT ID
NCT05915442About Quemliclustat + Etrumadenant + Zimberelimab
Quemliclustat + Etrumadenant + Zimberelimab is a phase 2 stage product being developed by Arcus Biosciences for Oligometastatic Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05915442. Target conditions include Oligometastatic Prostate Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Oligometastatic Prostate Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05915442 | Phase 2 | Recruiting |
Competing Products
5 competing products in Oligometastatic Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium Lu-177 PNT2002 | Eli Lilly | Phase 2 | 39 |
| Pembrolizumab | Merck | Phase 2 | 42 |
| Pembrolizumab | Merck | Phase 3 | 47 |
| AAA617 | Novartis | Phase 3 | 47 |
| Actinium Ac 225 Vipivotide Tetraxetan + Lutetium Lu 177 Vipivotide Tetraxetan | Novartis | Phase 2 | 42 |